DK3442538T3 - Behandling af levodopa-induceret dyskinesi med trapidil - Google Patents
Behandling af levodopa-induceret dyskinesi med trapidilInfo
- Publication number
- DK3442538T3 DK3442538T3 DK17779608.3T DK17779608T DK3442538T3 DK 3442538 T3 DK3442538 T3 DK 3442538T3 DK 17779608 T DK17779608 T DK 17779608T DK 3442538 T3 DK3442538 T3 DK 3442538T3
- Authority
- DK
- Denmark
- Prior art keywords
- trapidil
- levodopa
- treatment
- induced dyskinesia
- dyskinesia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Catching Or Destruction (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317983P | 2016-04-04 | 2016-04-04 | |
| PCT/US2017/025788 WO2017176652A2 (en) | 2016-04-04 | 2017-04-03 | Treating extrapyramidal syndrome using trapidil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3442538T3 true DK3442538T3 (da) | 2025-09-01 |
Family
ID=60001402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17779608.3T DK3442538T3 (da) | 2016-04-04 | 2017-04-03 | Behandling af levodopa-induceret dyskinesi med trapidil |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10350212B2 (https=) |
| EP (1) | EP3442538B1 (https=) |
| JP (3) | JP7049683B2 (https=) |
| CN (2) | CN116509869A (https=) |
| AU (1) | AU2017246334C1 (https=) |
| CA (1) | CA3054674A1 (https=) |
| DK (1) | DK3442538T3 (https=) |
| ES (1) | ES3039958T3 (https=) |
| FI (1) | FI3442538T3 (https=) |
| WO (1) | WO2017176652A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7049683B2 (ja) | 2016-04-04 | 2022-04-07 | シノピア バイオサイエンシーズ，インク． | トラピジルを使用する錐体外路症候群の処置 |
| US11517548B2 (en) | 2018-07-19 | 2022-12-06 | Impel Pharmaceuticals Inc. | Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease |
| CA3163242A1 (en) * | 2019-12-02 | 2021-06-10 | Aarash BORDBAR | Treating cognitive disorders using trapidil |
| MX2022011879A (es) * | 2020-03-26 | 2023-01-11 | Sinopia Biosciences Inc | Derivados de trapidilo marcados isotopicamente. |
| WO2024053728A1 (ja) * | 2022-09-09 | 2024-03-14 | 住友ファーマ株式会社 | 対象の状態の予測およびその応用 |
| CN116754348B (zh) * | 2023-06-06 | 2024-03-08 | 华北理工大学 | 基于zif-8-90材料的泡腾片、其制备方法及其应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4739044A (en) | 1985-06-13 | 1988-04-19 | Amgen | Method for derivitization of polynucleotides |
| US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IT1222414B (it) | 1987-07-31 | 1990-09-05 | Chiesi Farma Spa | Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| US5994056A (en) | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
| US5770358A (en) | 1991-09-18 | 1998-06-23 | Affymax Technologies N.V. | Tagged synthetic oligomer libraries |
| JP3195391B2 (ja) | 1991-11-14 | 2001-08-06 | エスエス製薬株式会社 | 徐放性トラピジル錠 |
| HU227530B1 (en) | 1991-11-22 | 2011-07-28 | Warner Chilcott Company | Delayed-release compositions containing risedronate and process for their production |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
| US5567583A (en) | 1991-12-16 | 1996-10-22 | Biotronics Corporation | Methods for reducing non-specific priming in DNA detection |
| US5348853A (en) | 1991-12-16 | 1994-09-20 | Biotronics Corporation | Method for reducing non-specific priming in DNA amplification |
| US6033854A (en) | 1991-12-16 | 2000-03-07 | Biotronics Corporation | Quantitative PCR using blocking oligonucleotides |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| JP2616252B2 (ja) | 1992-10-16 | 1997-06-04 | 日本新薬株式会社 | ワックスマトリックスの製法 |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| DE19514048A1 (de) * | 1995-04-13 | 1996-10-17 | Rentschler Arzneimittel | Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5869717A (en) | 1997-09-17 | 1999-02-09 | Uop Llc | Process for inhibiting the polymerization of vinyl aromatics |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| JP2001322933A (ja) | 2000-05-15 | 2001-11-20 | Ucb Sa | Ｃｄ４０シグナル遮断剤 |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| WO2005007096A2 (en) * | 2003-07-11 | 2005-01-27 | Merck & Co., Inc. | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| US20080242657A1 (en) * | 2004-03-26 | 2008-10-02 | Marino Michael J | Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists |
| CN101360421B (zh) * | 2005-11-18 | 2014-06-18 | 康乃尔研究基金会有限公司 | 烟酰核苷组合物及其使用方法 |
| WO2009070805A2 (en) * | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009129537A2 (en) | 2008-04-18 | 2009-10-22 | Gary Zabow | Magnetic microstructures for magnetic resonance imaging |
| KR102759126B1 (ko) | 2010-12-30 | 2025-01-24 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| KR101534395B1 (ko) | 2013-08-01 | 2015-07-09 | 서울대학교산학협력단 | 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물 |
| WO2017059118A1 (en) * | 2015-09-29 | 2017-04-06 | Duke University | Compositions and methods for identifying and treating dystonia disorders |
| US11281170B2 (en) | 2015-12-29 | 2022-03-22 | Jones And Malterer Technology Innovations Incorporated | Multi-point synchronizable and scalable lighting control systems |
| JP7049683B2 (ja) | 2016-04-04 | 2022-04-07 | シノピア バイオサイエンシーズ，インク． | トラピジルを使用する錐体外路症候群の処置 |
| MX2022011879A (es) | 2020-03-26 | 2023-01-11 | Sinopia Biosciences Inc | Derivados de trapidilo marcados isotopicamente. |
-
2017
- 2017-04-03 JP JP2019502544A patent/JP7049683B2/ja active Active
- 2017-04-03 ES ES17779608T patent/ES3039958T3/es active Active
- 2017-04-03 WO PCT/US2017/025788 patent/WO2017176652A2/en not_active Ceased
- 2017-04-03 CN CN202310643240.2A patent/CN116509869A/zh active Pending
- 2017-04-03 CA CA3054674A patent/CA3054674A1/en active Pending
- 2017-04-03 AU AU2017246334A patent/AU2017246334C1/en active Active
- 2017-04-03 DK DK17779608.3T patent/DK3442538T3/da active
- 2017-04-03 FI FIEP17779608.3T patent/FI3442538T3/fi active
- 2017-04-03 CN CN201780034722.0A patent/CN109310700A/zh active Pending
- 2017-04-03 EP EP17779608.3A patent/EP3442538B1/en active Active
-
2018
- 2018-04-25 US US15/962,999 patent/US10350212B2/en active Active
-
2019
- 2019-07-03 US US16/503,128 patent/US11628170B2/en active Active
-
2022
- 2022-03-18 JP JP2022044284A patent/JP7794668B2/ja active Active
-
2023
- 2023-03-01 US US18/176,962 patent/US12268691B2/en active Active
-
2024
- 2024-03-15 JP JP2024041690A patent/JP2024095682A/ja active Pending
-
2025
- 2025-01-16 US US19/025,296 patent/US20250387396A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11628170B2 (en) | 2023-04-18 |
| AU2017246334B2 (en) | 2022-07-28 |
| WO2017176652A3 (en) | 2018-05-17 |
| AU2017246334C1 (en) | 2022-11-17 |
| JP7049683B2 (ja) | 2022-04-07 |
| FI3442538T3 (fi) | 2025-09-04 |
| US20250387396A1 (en) | 2025-12-25 |
| ES3039958T3 (en) | 2025-10-27 |
| EP3442538A2 (en) | 2019-02-20 |
| US20230201205A1 (en) | 2023-06-29 |
| JP2022088469A (ja) | 2022-06-14 |
| EP3442538B1 (en) | 2025-07-23 |
| WO2017176652A2 (en) | 2017-10-12 |
| CN109310700A (zh) | 2019-02-05 |
| AU2017246334A1 (en) | 2018-11-15 |
| JP2024095682A (ja) | 2024-07-10 |
| EP3442538A4 (en) | 2019-11-20 |
| US20180243307A1 (en) | 2018-08-30 |
| US12268691B2 (en) | 2025-04-08 |
| CN116509869A (zh) | 2023-08-01 |
| JP2019510826A (ja) | 2019-04-18 |
| US10350212B2 (en) | 2019-07-16 |
| JP7794668B2 (ja) | 2026-01-06 |
| CA3054674A1 (en) | 2017-12-10 |
| US20190328741A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3515937T3 (da) | Behandling af refraktorisk migræne | |
| DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| DK3244965T3 (da) | Behandling af hovedpine med elektrisk stimulering | |
| DK3302565T3 (da) | Faste doseringsformer af palbociclib | |
| DK3117310T3 (da) | Håndtering af behandling associeret med valgte arkitektoniske indretninger | |
| DK3973959T3 (da) | Behandling af kolestatisk kløe med seladelpar | |
| DK3506904T3 (da) | Behandling af demens | |
| DK3021838T3 (da) | Behandling af fedme | |
| EP3314594A4 (en) | SMART STAY-DAY | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3419622T3 (da) | Behandling af neurodegenerativ øjensygdom med pridopidin | |
| DK3303614T3 (da) | Forbedret anvendelse af overfladeprimere i klynger | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3294532T3 (da) | Forbedringer i forbindelse med fremstilling af vindmøllekomponenter | |
| DK3297654T3 (da) | Behandling af post-bariatrisk hypoglykæmi med exendin(9-39) | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3442538T3 (da) | Behandling af levodopa-induceret dyskinesi med trapidil | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3390422T3 (da) | Krystalformer af lnt | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| IL254825A0 (en) | Methods of treatment with taselisib |